Beta3-adrenergic receptors (β3-AR) have emerged as pivotal modulators of cardiac performance, particularly in the context of heart failure. Distinct from the classical β1/β2-adrenergic signalling ...
Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback